Effect of Pioglitazone on T2DM Patients With COVID-19
A phase 4 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 1506 participants.
Also called NCT04604223
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 1,506 participants
- Sponsor
- Dasman Diabetes Institute
- Registry
-
NCT04604223
-
- Other papers using this trial's data
- Effect of pioglitazone on inflammatory response and clinical outcome in T2DM patients with COVID-19: a randomized multicenter double-blind clinical trial
- Started
- (actual)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Kuwait, Qatar
- Registry status
- Unknown status
Technical summary
Registry record NCT04604223. Randomized; quadruple masking; primary purpose treatment. Start 2021-01-18 (actual); primary completion 2021-06-29 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Effect of Pioglitazone on T2DM Patients With COVID-19
- Acronym
- PIOQ8
- Condition
- Covid19
- Condition
- Type 2 Diabetes
- Intervention (Drug)
- Pioglitazone 45 mg
- Lead sponsor
- Dasman Diabetes Institute
- Collaborator
- Ministry of Health, Kuwait
- Collaborator
- Texas Diabetes Institute
- Collaborator
- Kuwait University
Record details
- Record id
cardio:ct-nct04604223- Content hash
a155ecfd6dd1d9b04fe73e2d2541bc845e04d1ff36407b5986f012bc154e5853